Comparison · NCT01727089-45f3a753
Arm I (Bevacizumab) vs Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105): Number of Participants With Overall Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Bevacizumab) vs Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105): Number of Participants With Overall Response. Trial comparisons, record NCT01727089-45f3a753. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01727089-45f3a753
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0345 | 0.00611 | 0.172 | wilson | |
| Risk in group 2 | 0.0333 | 0.00591 | 0.167 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00115 | -0.135 | 0.141 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.0678 | 15.8 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.0617 | 17.4 | log | |
| Number needed to treat, for one more participant with the outcome on Arm I (Bevacizumab) than on Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105) | 870 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Bevacizumab) | Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~Bevacizumab: Given IV~Laboratory Biomarker Analysis: Correlative studies | 1 | 29 | OG000 |
| Group 2 | Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105) | Patients receive 10 mg\\kg bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 10 mg\\kg IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~Anti-Endoglin Chimeric Monoclonal Antibody TRC105: Given IV~Bevacizumab: Given IV~Laboratory Biomarker Analysis: Correlative studies~Pharmacological Study: Correlative studies | 1 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Overall Response
- Description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
- Time frame
- From time of treatment initiation until conclusion of treatment, assessed every 12 weeks.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
- NCT number
- NCT01727089
- Phases
- PHASE2
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
- Interventions
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2018-06-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01727089?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01727089-45f3a753